RNA

AbbVie to Acquire Capstan Therapeutics for $2 Billion

AbbVie has announced it will acquire Capstan Therapeutics, a clinical-stage biotechnology company focused on advancing in vivo cell engineering through RNA delivery using targeted lipid nanoparticles (tLNPs).

News

Wacker and CordenPharma in RNA Drugs Project

Together with Munich’s Ludwig Maximilian University (LMU) and the Humboldt University of Berlin (HU Berlin), German companies Wacker Chemie and CordenPharma International have launched a three-year project to accelerate the development of RNA-based drugs.

Topics • Strategy

Innovative Companies Have to Deal with Risks

News

Silence Buys Into Arrowhead Pharmaceuticals

Top-Feature

Sasol

From Data to Decisions: Digital Tools Reshaping the Chemical and Life Sciences Landscape

Brenntag SE

Brenntag Downsizes Management Board, Retains Both Divisions

Bio-Rad Laboratories

Dual‑Targeting Breakthroughs: Advancements in Bispecific Antibody Development

Dow Chemical Company

Anchored in Sustainability

Special Issue

Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

AbbVie Inc.

RNA

AbbVie to Acquire Capstan Therapeutics for $2 Billion

Wacker and CordenPharma in RNA Drugs Project

Innovative Companies Have to Deal with Risks

Silence Buys Into Arrowhead Pharmaceuticals

Top-Feature

Leading Transformation

Leading the way. Driving results.

Welcome to the World of Laboratories: Analytica 2026

Advanced Recycling Conference 2025: New Paths to the Circular Economy

ECA Foundation Aims to Become Largest Pharma Association for GMP/GDP Compliance